Director, Center for the Evaluation of Value and Risk in Health
Institute for Clinical Research and Health Policy Studies
Tufts Medical Center
Professor, Tufts University School of Medicine
Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care.
Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He served as co-chair of the 2nd Panel on Cost-Effectiveness in Health and Medicine. He is the author or co-author of over 300 papers in the medical literature, and the author or co-author of 3 books: Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) ; Cost-Effectiveness in Health and Medicine, 2nd Edition (Oxford University Press, 2017); The Right Price: A Value-Based Prescription for Drug Costs (Oxford University Press, 2021).
Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is a member of the editorial advisory board of Health Affairs and the health policy advisory board for the Congressional Budget Office. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University.
Daniel Ollendorf, PhD, MPH – Co-Chair
Director of Value Measurements and Global Health Initiatives, CEVR
Assistant Professor of Medicine, Tufts University School of Medicine
Dr. Daniel Ollendorf’s research interests include expanding the use of health technology assessment (HTA) and economic evaluation in low- and middle-income countries, as well as refinement and use of value assessment tools in the US and other high-income settings. Prior to joining CEVR, Dan was Chief Scientific Officer for the Institute for Clinical and Economic Review (ICER) for over 10 years, where he oversaw the broader HTA process and managed relationships with multiple stakeholders and research collaborators.
Dr. Ollendorf is non-resident Fellow in Global Health at the Center for Global Development, and currently serves as the Chair of the Health Technology Assessment International (HTAi) Global Policy Forum.
He received his PhD in Clinical Epidemiology from the University of Amsterdam, and an MPH in Health Policy & Management/Epidemiology from Boston University.
Elisabeth Oehrlein, PhD
Founder, Applied Patient Experiences, LLC
Elisabeth M. Oehrlein, Ph.D., MS, is a mixed-methods researcher with expertise in patient engagement and the role of patient experience data in drug development, value/health technology assessment, and real-world research. Before founding Applied Patient Experience, LLC, Dr. Oehrlein served on the senior leadership team at the National Health Council, where she was responsible for research and education programs. She has spoken widely on the topic of patient-centered research, including invited presentations at the National Academy of Sciences, the Council for International Organizations of Medical Sciences, and various Congressional Briefings.
She is an active member of HTAi’s Patient and Citizen Involvement Group, as well as the International Society for Pharmacoeconomics and Outcomes Research, where she has held leadership roles in the Patient-Centered and Real-World Evidence Special Interest Groups and is faculty for the short course “An Introduction to Patient-Focused Medical Product Development.” She has published widely in medical, economic, and health policy journals and serves as an Associate Editor of Value in Health.
Dr. Oehrlein holds a BA from Franklin & Marshall College, an MS in Epidemiology from the University of Maryland School of Medicine’s Department of Epidemiology and Human Genetics, and a Ph.D. in Pharmaceutical Health Services Research from the University of Maryland School of Pharmacy.
Darius Lakdawalla, PhD
Quintiles Chair in Pharmaceutical Development and Regulatory Innovation
Director of Research, USC Schaeffer Center
Darius Lakdawalla, PhD is a widely published, award-winning researcher and a leading authority on health economics and health policy. He holds the Quintiles Chair in Pharmaceutical Development and Regulatory Innovation at the University of Southern California, where he sits on the faculties of the School of Pharmacy, the Sol Price School of Public Policy, and the Leonard D. Schaeffer Center for Health Policy and Economics, one of the nation’s premier health policy research centers.
His research has focused primarily on the economics of risks to health, the value and determinants of medical innovation, the economics of health insurance markets, and the industrial organization of healthcare markets. His work has appeared in leading peer-reviewed journals of economics, health policy, and medicine, including the American Economic Review, Quarterly Journal of Economics, Health Affairs, the Journal of Health Economics, and the New England Journal of Medicine. In addition, his work has been featured by prominent popular press outlets, such as the Wall Street Journal, National Public Radio, Forbes, and the New York Times.
Dr. Lakdawalla is currently a Research Associate at the National Bureau of Economic Research in Cambridge, MA. He serves as an Associate Editor for the Journal of Health Economics, and he previously served as Associate Editor for the Review of Economics and Statistics and the American Journal of Health Economics. Dr. Lakdawalla is also a past winner of both the annual Milken Institute Award for Distinguished Economic Research Award (for best research in the field of economics) and the Eugene Garfield Economic Impact of Medical and Health Research Award (for best research on medical innovation). He has also received the PhRMA Foundation Value Assessment Challenge Award, designed to encourage innovative approaches to defining and measuring value in health care, in 2019 (third place) and 2020 (first place).
Dr. Lakdawalla received his Ph.D. in economics from the University of Chicago and his B.A. in mathematics and philosophy from Amherst College (Summa Cum Laude and Phi Beta Kappa).
Chris Whaley, PhD
Health Economist, RAND Corporation
Professor, RAND Pardee Graduate School
Dr. Chris Whaley's research focuses on health care price transparency and market structure. His research has been published in leading clinical, health policy, and economics journals. It has been covered in the New York Times, the Wall Street Journal, Forbes, and CNN. Dr. Whaley has presented results to state and federal policy makers, including the California State Assembly, the Congressional Budget Office, and the Federal Trade Commission.
Dr. Whaley is a health economist at the RAND Corporation and professor at the RAND Pardee Graduate School. He received his PhD in Health Economics from the University of California, Berkeley.
Naomi Aronson, PhD
Executive Director, Clinical Evaluation and Innovation Blue Cross Blue Shield Association (BCBSA)
Dr. Naomi Aronson leads BCBSA clinical effectiveness engagement with regulatory agencies and policy consortia. Her areas of leadership include comparative effectiveness, patient centered research, safety surveillance, regulatory science and methodological standards. She is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), the Health Technology Assessment International Health Policy Forum, the New Drug Development Paradigms (NEWDIGS) initiative of the MIT Center for Biomedical Innovation, and the Medical Device Innovation Consortium (MDIC) National Evaluation System for Health Technology (NEST) Governing Committee.
Siyu Ma, PhD
Senior Research Scientist, CEVR, Tufts Medical Center
Siyu Ma, PhD is a Senior Research Scientist at the Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. Dr. Ma’s research focuses on examining the outcomes and economic value of health interventions, factors that influence medication adherence, and the clinical and economic burden of diseases.
Dr. Ma completed her Post-Doctoral training at Tufts Medical Center, and holds a PhD in Health Policy from Brandeis University.
The Research Consortium for Health Care Value Assessment is a partnership between Altarum and VBID Health, with funding from the PhRMA Foundation as part of its Value Assessment Initiative, established to promote the pursuit of value in health care delivery in the U.S. Follow us at @ValueConsortium.
Beth Beaudin-Seiler, Ph.D.
3520 Green Court, Suite 300
Ann Arbor, MI 48105